<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Rein Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/rein-therapeutics-inc</link>
<description>Latest news and press releases for Rein Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 29 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/rein-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835b97f78dffbe2df1157a4.webp</url>
<title>Rein Therapeutics Inc</title>
<link>https://6ix.com/company/rein-therapeutics-inc</link>
</image>
<item>
<title>Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis</title>
<link>https://6ix.com/company/rein-therapeutics-inc/news/rein-therapeutics-provides-clinical-trial-update-for-phase-2-renew-study-of-lti-03-in-idiopathic-pulmonary-fibrosis</link>
<guid isPermaLink="true">https://6ix.com/company/rein-therapeutics-inc/news/rein-therapeutics-provides-clinical-trial-update-for-phase-2-renew-study-of-lti-03-in-idiopathic-pulmonary-fibrosis</guid>
<pubDate>Wed, 29 Apr 2026 12:00:00 GMT</pubDate>
<description>Patient enrollment accelerates across expanding number of clinical trial sites in multiple countries 8 patients enrolled, with additional patients expected in the near termEnrollment initiated in March 2026, with patients being added on a regular basisClinical trial sites active in the United States, Australia, and Poland, with additional countries expected to open in the near term AUSTIN, Texas, April 29, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical co</description>
</item>
<item>
<title>Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis</title>
<link>https://6ix.com/company/rein-therapeutics-inc/news/rein-therapeutics-doses-first-patient-in-phase-2-trial-of-lti-03-for-idiopathic-pulmonary-fibrosis</link>
<guid isPermaLink="true">https://6ix.com/company/rein-therapeutics-inc/news/rein-therapeutics-doses-first-patient-in-phase-2-trial-of-lti-03-for-idiopathic-pulmonary-fibrosis</guid>
<pubDate>Tue, 03 Mar 2026 05:00:00 GMT</pubDate>
<description>Randomized, placebo-controlled study to evaluate safety, tolerability, and potential for positive impact on lung function AUSTIN, Texas, March 03, 2026 (GLOBE</description>
</item>
<item>
<title>Rein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary Fibrosis</title>
<link>https://6ix.com/company/rein-therapeutics-inc/news/rein-therapeutics-receives-orphan-drug-130000545</link>
<guid isPermaLink="true">https://6ix.com/company/rein-therapeutics-inc/news/rein-therapeutics-receives-orphan-drug-130000545</guid>
<pubDate>Tue, 20 Jan 2026 13:00:00 GMT</pubDate>
<description>-- Designation highlights significant unmet medical needAUSTIN, Texas, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced that it has received orphan drug designation from the European Medicines Agency (EMA) for LTI-03, its lead drug candidate aimed at preserving lung function in patients wi</description>
</item>
<item>
<title>Rein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPF</title>
<link>https://6ix.com/company/rein-therapeutics-inc/news/rein-therapeutics-announces-scientific-publication-123000862</link>
<guid isPermaLink="true">https://6ix.com/company/rein-therapeutics-inc/news/rein-therapeutics-announces-scientific-publication-123000862</guid>
<pubDate>Thu, 06 Nov 2025 12:30:00 GMT</pubDate>
<description>New data builds on prior results, highlights LTI-03's differentiated approach, and supports the ongoing global Phase 2 RENEW trialAUSTIN, Texas, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced that a new preprint has been posted to medRxiv describing clinical and translational findings fr</description>
</item>
<item>
<title>Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis</title>
<link>https://6ix.com/company/rein-therapeutics-inc/news/rein-therapeutics-receives-fda-clearance-123000688</link>
<guid isPermaLink="true">https://6ix.com/company/rein-therapeutics-inc/news/rein-therapeutics-receives-fda-clearance-123000688</guid>
<pubDate>Mon, 03 Nov 2025 12:30:00 GMT</pubDate>
<description>FDA lifts clinical hold following review of Company’s Complete Response submission.Company expects to restart U.S. enrollment in late 2025 or early 2026 across 20 clinical sites.Early data suggests that LTI-03 may not only slow fibrosis but also promote lung healing. AUSTIN, Texas, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulm</description>
</item>
<item>
<title>Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis</title>
<link>https://6ix.com/company/rein-therapeutics-inc/news/rein-therapeutics-receives-european-regulatory-113000390</link>
<guid isPermaLink="true">https://6ix.com/company/rein-therapeutics-inc/news/rein-therapeutics-receives-european-regulatory-113000390</guid>
<pubDate>Thu, 09 Oct 2025 11:30:00 GMT</pubDate>
<description>EMA approval covers study sites in Germany and Poland as part of the Company’s global Phase 2 RENEW trialTrial will evaluate LTI-03, a first-in-class therapy designed to both reduce lung scarring and promote repair AUSTIN, Texas, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that</description>
</item>
<item>
<title>Rein Therapeutics Announces Publication of New Translational Data in iScience on Company’s Novel Therapy for Idiopathic Pulmonary Fibrosis</title>
<link>https://6ix.com/company/rein-therapeutics-inc/news/rein-therapeutics-announces-publication-translational-113000779</link>
<guid isPermaLink="true">https://6ix.com/company/rein-therapeutics-inc/news/rein-therapeutics-announces-publication-translational-113000779</guid>
<pubDate>Wed, 17 Sep 2025 11:30:00 GMT</pubDate>
<description>Peer-reviewed publication highlights potential breakthrough anti-fibrotic properties of LTI-03 in lung tissue from IPF patientsAUSTIN, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced the publication of novel data on its lead drug candidate, LTI-03, in iScience, a peer-review</description>
</item>
<item>
<title>Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis</title>
<link>https://6ix.com/company/rein-therapeutics-inc/news/rein-therapeutics-wins-u-k-120000179</link>
<guid isPermaLink="true">https://6ix.com/company/rein-therapeutics-inc/news/rein-therapeutics-wins-u-k-120000179</guid>
<pubDate>Tue, 19 Aug 2025 12:00:00 GMT</pubDate>
<description>AUSTIN, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the Company to initiate its Phase 2 “RENEW” clinical trial of LTI-03, the Company’s lead drug candidate for idiopathic pulmonary fibrosis (IP</description>
</item>
<item>
<title>Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025</title>
<link>https://6ix.com/company/rein-therapeutics-inc/news/rein-therapeutics-present-novel-ipf-210000914</link>
<guid isPermaLink="true">https://6ix.com/company/rein-therapeutics-inc/news/rein-therapeutics-present-novel-ipf-210000914</guid>
<pubDate>Thu, 14 Aug 2025 21:00:00 GMT</pubDate>
<description>AUSTIN, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced that Chief Scientific Officer, Cory Hogaboam, and Chief Executive Officer, Brian Windsor, will each present at the IPF Summit 2025, taking place August 19-21, 2025, in Boston, MA. Dr. Hogaboam will present at 8:00 am on Tuesda</description>
</item>
<item>
<title>Rein Therapeutics Enters into Agreements for up to $21 Million in Flexible Financing</title>
<link>https://6ix.com/company/rein-therapeutics-inc/news/rein-therapeutics-enters-agreements-21-123000127</link>
<guid isPermaLink="true">https://6ix.com/company/rein-therapeutics-inc/news/rein-therapeutics-enters-agreements-21-123000127</guid>
<pubDate>Wed, 30 Jul 2025 12:30:00 GMT</pubDate>
<description>- Financing designed to support Phase 2 IPF trial and pipeline advancementAUSTIN, Texas, July 30, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that it has entered into two strategic financing agreements with an affiliate of Yorkville Advisors Global, LP, providing the potential for access</description>
</item>
<item>
<title>Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders</title>
<link>https://6ix.com/company/rein-therapeutics-inc/news/rein-therapeutics-announces-adjournment-annual-141100615</link>
<guid isPermaLink="true">https://6ix.com/company/rein-therapeutics-inc/news/rein-therapeutics-announces-adjournment-annual-141100615</guid>
<pubDate>Tue, 24 Jun 2025 14:11:00 GMT</pubDate>
<description>Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medications to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that it adjourned, without conducting any business, the 2025 annual meeting of stockholders (the "Annual Meeting") on Tuesday, June 24, 2025, due to the fact that a quorum was not achieved and to allow more opportunity for Company stockholders to vote on all proposal</description>
</item>
<item>
<title>Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF</title>
<link>https://6ix.com/company/rein-therapeutics-inc/news/rein-therapeutics-announces-first-patient-110000006</link>
<guid isPermaLink="true">https://6ix.com/company/rein-therapeutics-inc/news/rein-therapeutics-announces-first-patient-110000006</guid>
<pubDate>Tue, 27 May 2025 11:00:00 GMT</pubDate>
<description>Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced today that the first patient has been dosed in the RENEW Phase 2 trial of its lead asset, LTI-03, a novel, multi-pathway, Caveolin-1-related peptide for the treatment of IPF.</description>
</item>
<item>
<title>Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference</title>
<link>https://6ix.com/company/rein-therapeutics-inc/news/rein-therapeutics-presents-two-posters-205100005</link>
<guid isPermaLink="true">https://6ix.com/company/rein-therapeutics-inc/news/rein-therapeutics-presents-two-posters-205100005</guid>
<pubDate>Mon, 19 May 2025 20:51:00 GMT</pubDate>
<description>Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that the Company and its collaborators presented two posters supporting the potential therapeutic effectiveness of LTI-03 in idiopathic pulmonary fibrosis (IPF) at the American Thoracic Society (ATS) 2025 International Conference.</description>
</item>
<item>
<title>Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/rein-therapeutics-inc/news/rein-therapeutics-reports-first-quarter-200900892</link>
<guid isPermaLink="true">https://6ix.com/company/rein-therapeutics-inc/news/rein-therapeutics-reports-first-quarter-200900892</guid>
<pubDate>Thu, 15 May 2025 20:09:00 GMT</pubDate>
<description>Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today reported financial results for the first quarter ended March 31, 2025 and provided a business update.</description>
</item>
<item>
<title>Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF</title>
<link>https://6ix.com/company/rein-therapeutics-inc/news/rein-therapeutics-announces-initiation-renew-110000149</link>
<guid isPermaLink="true">https://6ix.com/company/rein-therapeutics-inc/news/rein-therapeutics-announces-initiation-renew-110000149</guid>
<pubDate>Mon, 12 May 2025 11:00:00 GMT</pubDate>
<description>Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that the RENEW Phase 2 trial of its lead asset, LTI-03, a novel, multi-pathway, Caveolin-1-related peptide for the treatment of idiopathic pulmonary fibrosis (IPF), has been initiated with screening and recruitment of patients underway.</description>
</item>
<item>
<title>Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF</title>
<link>https://6ix.com/company/rein-therapeutics-inc/news/rein-therapeutics-qureight-ltd-announce-110000614</link>
<guid isPermaLink="true">https://6ix.com/company/rein-therapeutics-inc/news/rein-therapeutics-qureight-ltd-announce-110000614</guid>
<pubDate>Thu, 01 May 2025 11:00:00 GMT</pubDate>
<description>Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, and Qureight Ltd, a Core Imaging Laboratory developing deep-learning image analytics, today announced a collaboration for the integration of Qureight's deep-learning platform into Rein's planned Phase 2 trial of its lead asset LTI-03, a novel, multi-pathway, Caveolin-1-related peptide</description>
</item>
<item>
<title>Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025</title>
<link>https://6ix.com/company/rein-therapeutics-inc/news/rein-therapeutics-present-citizens-life-200500850</link>
<guid isPermaLink="true">https://6ix.com/company/rein-therapeutics-inc/news/rein-therapeutics-present-citizens-life-200500850</guid>
<pubDate>Wed, 30 Apr 2025 20:05:00 GMT</pubDate>
<description>Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that Brian Windsor, Ph.D., President and Chief Executive Officer, will present at The Citizens Life Sciences Conference 2025 on Thursday, May 8, 2025 at 12:00 p.m. EDT in New York, NY.</description>
</item>
<item>
<title>Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference</title>
<link>https://6ix.com/company/rein-therapeutics-inc/news/rein-therapeutics-announces-abstract-accepted-110000640</link>
<guid isPermaLink="true">https://6ix.com/company/rein-therapeutics-inc/news/rein-therapeutics-announces-abstract-accepted-110000640</guid>
<pubDate>Mon, 28 Apr 2025 11:00:00 GMT</pubDate>
<description>Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that an abstract has been accepted at the American Thoracic Society (ATS) 2025 International Conference taking place May 18-21, 2025 in San Francisco, CA.</description>
</item>
<item>
<title>Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases</title>
<link>https://6ix.com/company/rein-therapeutics-inc/news/rein-therapeutics-granted-two-patents-110000819</link>
<guid isPermaLink="true">https://6ix.com/company/rein-therapeutics-inc/news/rein-therapeutics-granted-two-patents-110000819</guid>
<pubDate>Wed, 23 Apr 2025 11:00:00 GMT</pubDate>
<description>Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that the U.S. Patent and Trademark Office (USPTO) granted two new patents related to Rein's lead product candidate, LTI-03, a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling, whic</description>
</item>
<item>
<title>Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F</title>
<link>https://6ix.com/company/rein-therapeutics-inc/news/rein-therapeutics-announces-publication-biomedicines-110000178</link>
<guid isPermaLink="true">https://6ix.com/company/rein-therapeutics-inc/news/rein-therapeutics-announces-publication-biomedicines-110000178</guid>
<pubDate>Tue, 15 Apr 2025 11:00:00 GMT</pubDate>
<description>Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced a publication highlighting the therapeutic potential of Caveolin-1-related peptide LTI-2355 in Idiopathic Pulmonary Fibrosis (IPF) and Post-Acute Sequelae of COVID Fibrosis (PASC-F) in the peer-reviewed journal, Biomedicines.</description>
</item>
</channel>
</rss>